Novel drugs in the management of difficult-to-treat hepatitis C genotypes
Emily J Cartwright, Lesley MillerDepartment of Medicine, Emory University School of Medicine, Atlanta, GA, USABackground: Hepatitis C virus (HCV) infection is the most common chronic bloodborne infection in the United States, with approximately 3.2 million Americans being chronically infected. Rates...
Enregistré dans:
Auteurs principaux: | Cartwright EJ, Miller L |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2013
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/8718e45ca68e48eea21d3274048d5dbc |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia
par: Danish FA, et autres
Publié: (2013) -
Hepatitis C infection in Egypt: prevalence, impact and management strategies [Corrigendum]
par: Gomaa A, et autres
Publié: (2017) -
Difficult bile duct cannulation: Do all roads lead to Rome?
par: Marianna Arvanitakis
Publié: (2021) -
Hepatitis C in Argentina: epidemiology and treatment
par: Gaite LA, et autres
Publié: (2014) -
Patients in the indeterminate phase of chronic hepatitis B virus infection should be treated
par: JIANG Yingying
Publié: (2021)